Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Carol A. Connell"'
Autor:
George A. Karpouzas, Zoltán Szekanecz, Eva Baecklund, Ted R. Mikuls, Deepak L. Bhatt, Cunshan Wang, Gosford A. Sawyerr, Yan Chen, Sujatha Menon, Carol A. Connell, Steven R. Ytterberg, Mahta Mortezavi
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 15 (2023)
Background: In patients with rheumatoid arthritis (RA), persistent inflammation and increasing disease activity are associated with increased risk of adverse events (AEs). Objectives: To assess relationships between RA disease activity and AEs of int
Externí odkaz:
https://doaj.org/article/87609669a463447b9ca9297342cee922
Autor:
Karen E. Hansen, Mahta Mortezavi, Edward Nagy, Cunshan Wang, Carol A. Connell, Zaher Radi, Heather J. Litman, Giovanni Adami, Maurizio Rossini
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis. Methods: We analyzed pooled d
Externí odkaz:
https://doaj.org/article/1d9b75146dd846feab811b470e6f4c89
Autor:
Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh
Publikováno v:
ACR Open Rheumatology, Vol 3, Iss 3, Pp 173-184 (2021)
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease
Externí odkaz:
https://doaj.org/article/619fc16b87424da49083d4b79c261367
Autor:
Xiaoxing, Wang, Martin E, Dowty, Ann, Wouters, Svitlana, Tatulych, Carol A, Connell, Vu H, Le, Sakambari, Tripathy, Melissa T, O'Gorman, Jennifer A, Winton, Natalie, Yin, Hernan, Valdez, Bimal K, Malhotra
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 47:419-429
Abrocitinib is a Janus kinase 1-selective inhibitor for the treatment of moderate-to-severe atopic dermatitis. Abrocitinib is eliminated primarily by metabolism involving cytochrome P450 (CYP) enzymes. Abrocitinib pharmacologic activity is attributab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d9f03f3e879e1fde1420371ca744bcb
https://doi.org/10.1007/s13318-021-00745-6
https://doi.org/10.1007/s13318-021-00745-6
Autor:
Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls, Gary G. Koch, Roy Fleischmann, Jose L. Rivas, Rebecca Germino, Sujatha Menon, Yanhui Sun, Cunshan Wang, Andrea B. Shapiro, Keith S. Kanik, Carol A. Connell
Publikováno v:
New England Journal of Medicine. 386:316-326
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7068afb6d6a297eebff3488155e8013
https://doi.org/10.1056/nejmoa2109927
https://doi.org/10.1056/nejmoa2109927
Publikováno v:
Journal of Business Strategy. 43:135-147
Purpose Whether they support long-term growth companies, entrepreneurial firms or turnarounds, top teams need to make bold strategic investment choices in times of boom, bust or pandemic. This paper aims to discuss firm strategies, as evidenced by th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::656060b34a6d04909de08e0e53a71a9e
https://doi.org/10.1108/jbs-10-2020-0247
https://doi.org/10.1108/jbs-10-2020-0247
Autor:
Jeffrey R Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L Bhatt, Levent M Gunay, Naonobu Sugiyama, Carol A Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J Gómez-Reino
Publikováno v:
Annals of the rheumatic diseases.
ObjectivesTo evaluate malignancies and their associations with baseline risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).MethodsIn an open-label, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43fe645effc59e871be99b081599ddb
https://pubmed.ncbi.nlm.nih.gov/36600185
https://pubmed.ncbi.nlm.nih.gov/36600185
Autor:
Manfred Hauben, Keith S. Kanik, Joel M. Kremer, Jeffrey R. Curtis, Christina Charles-Schoeman, Alina Onofrei, Eric Hung, Stanley Cohen, Cunshan Wang, Hernan Valdez, Thomas V. Jones, Carol A. Connell, Philip J. Mease, Ann Madsen, Jeff Greenberg, Wendi Malley, Daniela Graham, Lara Fallon, John Woolcott, Huifeng Yun
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of an ongoing, open-label, bli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca1facef0a42177e63aeb8af03cb7910
http://europepmc.org/articles/PMC7569391
http://europepmc.org/articles/PMC7569391
Autor:
Andra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L Bhatt, Carol A Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B Shapiro, Janet E Pope, Hendrik Schulze-Koops
Publikováno v:
Annals of the rheumatic diseases. 81(11)
ObjectivesTo characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance.MethodsIn this open-label, randomised controlled trial, patients with RA aged≥50 years with ≥1 additional cardiovascular risk factor received tof
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf520a43b96109bf479685db9c91eb8b
https://pubmed.ncbi.nlm.nih.gov/35922124
https://pubmed.ncbi.nlm.nih.gov/35922124
Autor:
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, Deepak L Bhatt, Jon T Giles, Steven R Ytterberg, Gary G Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L Rivas, Arne Yndestad, Carol A Connell, Zoltan Szekanecz
Publikováno v:
Annals of the rheumatic diseases, vol 82, iss 1
ObjectivesEvaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dd751d070c6e43ca4999404b27b8612
https://pubmed.ncbi.nlm.nih.gov/36137735
https://pubmed.ncbi.nlm.nih.gov/36137735